About Castle Biosciences
Castle Biosciences is a Healthcare company based in Pittsburgh (United States) founded in 2008, and was acquired by Castle Biosciences in October 2021. It operates on a HealthTech model. Castle Biosciences has raised $14.18 million across 10 funding rounds from investors including UPMC, Castle Biosciences and NIH. Castle Biosciences offers products and services including TissueCypher, DecisionDx-Melanoma, DecisionDx-SCC, DecisionDx-UM, and MyPath Melanoma. Its focus areas include Biotechnology and Diagnostic Testing. Its legal entity is Castle Biosciences, Inc. Its competitors include PAVmed, Previse and Lucid Diagnostics; 2 of its 3 listed competitors have raised funding.
Company details
Precision diagnostic and prognostic tests are developed by Castle Biosciences for various medical conditions. Focus is placed on dermatology, gastroenterology, and ophthalmology sectors. Solutions such as TissueCypher for Barretts esophagus, DecisionDx-Melanoma for cutaneous melanoma, and DecisionDx-UM for uveal melanoma are provided. Risk stratification and personalized patient management are enabled through AI-driven spatial biology and gene expression profiling technologies. Clinical decision-making is supported by offering actionable insights to healthcare providers for cancer risk assessment and treatment planning.
- Headquarters Pittsburgh, United States
- Stage Acquired
- SectorsHealthcare
- Phone•••• ••••
- Website cernostics.com
- Social LinkedIn X Facebook Instagram YouTube
- Acquired by Castle Biosciences (Oct 2021)
- Legal Name Castle Biosciences, Inc.
- Total Equity Funding$14.18M (USD)
in 10 rounds
- Latest Funding Round$2.5M (USD), Series B
Mar 2018
- InvestorsUPMC
& 7 more
- Acquired byCastle Biosciences
(Oct 2021)
Products & Services of Castle Biosciences
Castle Biosciences offers a comprehensive portfolio of products and services, including TissueCypher, DecisionDx-Melanoma, DecisionDx-SCC, DecisionDx-UM, and MyPath Melanoma.
Risk of progression to esophageal cancer is predicted.
Melanoma progression risk is assessed for patients.
Squamous cell carcinoma risk is evaluated accurately.
Uveal melanoma metastatic risk is determined precisely.
Melanoma diagnosis is supported through tissue analysis.
Apps and channels of Castle Biosciences
its YouTube channel Castle Biosciences has 578 subscribers and 30 videos.
Videos from Castle Biosciences
The most watched videos on Castle Biosciences's YouTube channel, Castle Biosciences (578 subscribers). Click a video to play it here.
More on Castle Biosciences.
Funding Insights of Castle Biosciences
Castle Biosciences has successfully raised a total of $14.18M across 10 strategic funding rounds. The most recent funding activity was a Series B round of $2.5 million completed in March 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $14.18M
- Total Rounds 10
- Last Round Series B — $2.5M
- First Round $393,600
(Nov 2009)
- Investors Count 7
All 10 funding rounds of Castle Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2018 | $2.5M | Series B | – | Illumina Ventures | – |
| Aug 2016 | $5M | Series B | – | UPMC | |
| Oct 2015 | $1.2M | Grant | – | – | |
| Jun 2015 | $1.96M | Series B | – | – | – |
| Mar 2014 | $100,000 | Series B | – | – | |
| Jul 2013 | $1.42M | Series B | – | Novitas Capital, Geisinger | – |
| Aug 2012 | $125,000 | Series A | – | Ben Franklin Technology Partners | – |
| Mar 2012 | $55,000 | Series A | – | – | |
| Jun 2010 | $2.62M | Series A | – | – | – |
| Nov 2009 | $393,600 | Seed | – | – | – |
8 investors in total: 8 institutional.
Investors in Castle Biosciences
Castle Biosciences has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include UPMC, Castle Biosciences and NIH.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health tech startups are invested in by Illumina Ventures. | illuminaventures.com | Foster City, United States | ||
| novitascapital.com | ||||
Investment and support are provided for Pennsylvania's tech-based companies. | 1983 | benfranklin.org | State College, United States | |
Support is offered for life sciences startups in Pittsburgh. | 2002 | plsg.com | Pittsburgh, United States | |
Multispecialty hospitals are operated as a nationwide chain. | 1986 | upmc.com | United States | |
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Fully integrated healthcare organization | 1915 | geisinger.org | United States | |
Diagnostic tests for cancer prognosis are provided. | 2008 | castlebiosciences.com | Friendswood, United States |
Investor details for Castle Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Castle Biosciences
4 dated milestones of Castle Biosciences across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Castle Biosciences is founded.
- Funding First funding round of $394K.
- Funding Latest funding round, Series B, of $2.5M.
- Exit Acquired by Castle Biosciences.
Competitors of Castle Biosciences
Castle Biosciences has 3 listed competitors in our database, 2 of them funded. They include PAVmed, Previse and Lucid Diagnostics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| pavmed.com | 2014 | New York, United States | $845,000 | 107 | Developer of medical devices and biomarkers to detect various diseases | |
| previsedx.com | 2018 | Baltimore, United States | $5.39M | Cancer detection and prevention solutions are developed by Previse. | ||
| luciddx.com | 2018 | New York, United States | 74 | Diagnostic kits for esophageal cancer biomarkers are developed. |
Detailed competitors of Castle Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Gastroenterology
3 companies that operate in the same segment as Castle Biosciences (Gastroenterology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | |||
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | 411 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Castle Biosciences
Complete news archive for Castle Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Castle Biosciences
Castle Biosciences was founded in 2008 and raised its 1st funding round 1 year after it was founded.
Castle Biosciences is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.
Castle Biosciences is a funded company, having raised a total of $14.18M across 10 funding rounds to date. The company's 1st funding round was a Seed of $393.6K, raised on Nov 2009.
Precision diagnostic and prognostic tests are developed by Castle Biosciences for various medical conditions. Focus is placed on dermatology, gastroenterology, and ophthalmology sectors. Solutions such as TissueCypher for Barretts esophagus, DecisionDx-Melanoma for cutaneous melanoma, and DecisionDx-UM for uveal melanoma are provided. Risk stratification and personalized patient management are enabled through AI-driven spatial biology and gene expression profiling technologies. Clinical decision-making is supported by offering actionable insights to healthcare providers for cancer risk assessment and treatment planning.
Castle Biosciences's top competitors include Lucid Diagnostics, PAVmed and Previse.
Castle Biosciences offers TissueCypher, DecisionDx-Melanoma, DecisionDx-SCC, DecisionDx-UM, and MyPath Melanoma.
Castle Biosciences has 8 investors. Key investors include UPMC, Castle Biosciences, NIH, Geisinger, and Ben Franklin Technology Partners.
Castle Biosciences operates through Castle Biosciences, Inc..
Yes. Castle Biosciences was acquired by Castle Biosciences in October 2021.